{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:07:38Z","timestamp":1793412458799,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,2,28]],"date-time":"2024-02-28T00:00:00Z","timestamp":1709078400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["T32GM007546"],"award-info":[{"award-number":["T32GM007546"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000061","name":"National Institutes of Health Fogarty International Center","doi-asserted-by":"publisher","award":["R21TW011035"],"award-info":[{"award-number":["R21TW011035"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.jctube.2024.100425","type":"journal-article","created":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T04:34:44Z","timestamp":1709267684000},"page":"100425","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A teenage girl with altered mental status and paraparesis"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1729-0011","authenticated-orcid":false,"given":"Ryo","family":"Miyakawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Louie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Keh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Javid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel D.","family":"Ernst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neela","family":"Goswami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicia C.","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2024.100425_b0005","unstructured":"American Academy of Pediatrics. Committee on Infectious Diseases. Report of the Committee on Infectious Diseases. Evanston, Ill."},{"issue":"10","key":"10.1016\/j.jctube.2024.100425_b0010","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1128\/AAC.02784-14","article-title":"Linezolid manifests a rapid and dramatic therapeutic effect for patients with life-threatening tuberculous meningitis","volume":"58","author":"Sun","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jctube.2024.100425_b0015","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/INF.0000000000001114","article-title":"Linezolid is associated with improved early outcomes of childhood tuberculous meningitis","volume":"35","author":"Li","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"17","key":"10.1016\/j.jctube.2024.100425_b0020","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1056\/NEJMoa040573","article-title":"Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults","volume":"351","author":"Thwaites","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jctube.2024.100425_b0025","unstructured":"Committee on Infectious Diseases American Academy of Pediatrics. Red Book: 2021-2024 Report of the Committee on Infectious Diseases (32nd Edition). American Academy of Pediatrics; 2021."},{"key":"10.1016\/j.jctube.2024.100425_b0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.12688\/wellcomeopenres.15565.1","article-title":"High dose oral rifampicin to improve survival from adult tuberculous meningitis: a randomised placebo-controlled double-blinded phase III trial (the HARVEST study)","volume":"4","author":"Marais","year":"2019","journal-title":"Wellcome Open Res"},{"key":"10.1016\/j.jctube.2024.100425_b0035","doi-asserted-by":"crossref","unstructured":"Maitre T, Bonnet M, Calmy A, et al. Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial. Trials. Nov 08 2022;23(1):928. doi:10.1186\/s13063-022-06772-1.","DOI":"10.1186\/s13063-022-06772-1"},{"key":"10.1016\/j.jctube.2024.100425_b0040","unstructured":"Griffiths A. SURE: Short intensive treatment for children with tuberculous meningitis. Accessed 07\/19\/2023, https:\/\/www.isrctn.com\/ISRCTN40829906."},{"key":"10.1016\/j.jctube.2024.100425_b0045","unstructured":"National Institute of Allergy and Infectious Diseases. Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis. Accessed 07\/19\/2023, https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05383742."},{"key":"10.1016\/j.jctube.2024.100425_b0050","unstructured":"Chow F. Adjunctive Linezolid for the Treatment of Tuberculous Meningitis (ALTER). Accessed 07\/19\/2023, https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04021121."},{"key":"10.1016\/j.jctube.2024.100425_b0055","doi-asserted-by":"crossref","unstructured":"Sahib A, Bhatia R, Srivastava MVP, et al. Escalate: Linezolid as an add on treatment in the intensive phase of tubercular meningitis. A randomized controlled pilot trial. Tuberculosis (Edinb). Sep 2023;142:102351. doi:10.1016\/j.tube.2023.102351.","DOI":"10.1016\/j.tube.2023.102351"},{"issue":"8","key":"10.1016\/j.jctube.2024.100425_b0060","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1093\/cid\/ciac932","article-title":"A phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for human immunodeficiency virus-associated tuberculous meningitis: the LASER-TBM trial","volume":"76","author":"Davis","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.jctube.2024.100425_b0065","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/j.cmi.2023.03.021","article-title":"Which trial do we need? a global, adaptive, platform trial to reduce death and disability from tuberculous meningitis","volume":"29","author":"Thwaites","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jctube.2024.100425_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2023.102361","article-title":"Treatment of tuberculous meningitis: overdue for concerted action","volume":"142","author":"Wilkinson","year":"2023","journal-title":"Tuberculosis (Edinb)"},{"key":"10.1016\/j.jctube.2024.100425_b0075","doi-asserted-by":"crossref","unstructured":"Khan SF, Macauley T, Tong SYC, et al. When Ventricular Cerebrospinal Fluid Assessment Misleads: Basal Meningitis and the Importance of Lumbar Puncture Sampling. Open Forum Infect Dis. Jul 01 2019;6(7)doi:10.1093\/ofid\/ofz324.","DOI":"10.1093\/ofid\/ofz324"},{"issue":"8","key":"10.1016\/j.jctube.2024.100425_b0080","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1093\/cid\/cix540","article-title":"Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis","volume":"65","author":"Rohlwink","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2024.100425_b0085","doi-asserted-by":"crossref","unstructured":"Rohlwink UK, Figaji A, Wilkinson KA, et al. Tuberculous meningitis in children is characterized by compartmentalized immune responses and neural excitotoxicity. Nat Commun. Aug 21 2019;10(1):3767. doi:10.1038\/s41467-019-11783-9.","DOI":"10.1038\/s41467-019-11783-9"},{"issue":"3","key":"10.1016\/j.jctube.2024.100425_b0090","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1474-4422(07)70034-0","article-title":"Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an observational study","volume":"6","author":"Thwaites","year":"2007","journal-title":"Lancet Neurol"},{"issue":"21","key":"10.1016\/j.jctube.2024.100425_b0095","first-page":"16","article-title":"Paradoxical reaction in tuberculous meningitis: presentation, predictors and impact on prognosis","volume":"06","author":"Singh","year":"2016306","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jctube.2024.100425_b0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ijid.2020.09.1457","article-title":"Worsening CSF parameters after the start of anti-tuberculosis treatment predicts intracerebral tuberculoma development","volume":"101","author":"Lu","year":"2020","journal-title":"Int J Infect Dis"},{"issue":"3","key":"10.1016\/j.jctube.2024.100425_b0105","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/cid\/cis899","article-title":"Frequency, severity, and prediction of tuberculous meningitis immune reconstitution inflammatory syndrome","volume":"56","author":"Marais","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.jctube.2024.100425_b0110","doi-asserted-by":"crossref","first-page":"e1997","DOI":"10.1097\/MD.0000000000001997","article-title":"Paradoxical manifestation is common in HIV-negative tuberculous meningitis","volume":"95","author":"Tai","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.jctube.2024.100425_b0115","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2024.100425_b0120","doi-asserted-by":"crossref","first-page":"e01009","DOI":"10.1016\/j.idcr.2020.e01009","article-title":"Severe paradoxical reaction in tuberculous meningitis","volume":"23","author":"Donovan","year":"2021","journal-title":"IDCases"},{"key":"10.1016\/j.jctube.2024.100425_b0125","doi-asserted-by":"crossref","unstructured":"van Toorn R, Solomons RS, Seddon JA, Schoeman JF. Thalidomide Use for Complicated Central Nervous System Tuberculosis in Children: Insights From an Observational Cohort. Clin Infect Dis. 03 01 2021;72(5):e136-e145. doi:10.1093\/cid\/ciaa1826.","DOI":"10.1093\/cid\/ciaa1826"},{"key":"10.1016\/j.jctube.2024.100425_b0130","doi-asserted-by":"crossref","unstructured":"Keeley AJ, Parkash V, Tunbridge A, et al. Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases. Int J STD AIDS. 07 2020;31(8):808-812. doi:10.1177\/0956462420915394.","DOI":"10.1177\/0956462420915394"},{"issue":"12","key":"10.1016\/j.jctube.2024.100425_b0135","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/jpids\/piab094","article-title":"Infliximab for paradoxical reactions in pediatric central nervous system tuberculosis","volume":"10","author":"Abo","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"29","key":"10.1016\/j.jctube.2024.100425_b0140","doi-asserted-by":"crossref","first-page":"e11186","DOI":"10.1097\/MD.0000000000011186","article-title":"Intracranial tuberculous mass lesions treated with thalidomide in an immunocompetent child from a low tuberculosis endemic country: a case report","volume":"97","author":"Caraffa","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.jctube.2024.100425_b0145","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1086\/592695","article-title":"Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes","volume":"47","author":"Blackmore","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2024.100425_b0150","doi-asserted-by":"crossref","unstructured":"Santin M, Escrich C, Maj\u00f2s C, Llaberia M, Grijota MD, Grau I. Tumor necrosis factor antagonists for paradoxical inflammatory reactions in the central nervous system tuberculosis: Case report and review. Medicine (Baltimore). Oct 23 2020;99(43):e22626. doi:10.1097\/MD.0000000000022626.","DOI":"10.1097\/MD.0000000000022626"},{"key":"10.1016\/j.jctube.2024.100425_b0155","doi-asserted-by":"crossref","unstructured":"Marais BJ, Cheong E, Fernando S, et al. Use of Infliximab to Treat Paradoxical Tuberculous Meningitis Reactions. Open Forum Infect Dis. Jan 2021;8(1):ofaa604. doi:10.1093\/ofid\/ofaa604.","DOI":"10.1093\/ofid\/ofaa604"},{"issue":"3","key":"10.1016\/j.jctube.2024.100425_b0160","doi-asserted-by":"crossref","first-page":"156","DOI":"10.5694\/mja14.00716","article-title":"Infliximab therapy in two cases of severe neurotuberculosis paradoxical reaction","volume":"202","author":"Molton","year":"2015","journal-title":"Med J Aust"},{"key":"10.1016\/j.jctube.2024.100425_b0165","doi-asserted-by":"crossref","unstructured":"Manesh A, Gautam P, Selwyn Selva Kumar D, et al. Effectiveness of adjunctive high dose infliximab therapy to improve disability free survival among patients with severe CNS tuberculosis: a matched retrospective cohort study. Clin Infect Dis. Jul 05 2023;doi:10.1093\/cid\/ciad401.","DOI":"10.1093\/cid\/ciad401"},{"issue":"3","key":"10.1016\/j.jctube.2024.100425_b0170","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology biologics register (BSRBR)","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jctube.2024.100425_b0175","doi-asserted-by":"crossref","unstructured":"Zhang Z, Fan W, Yang G, et al. Risk of tuberculosis in patients treated with TNF-\u03b1 antagonists: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. Mar 22 2017;7(3):e012567. doi:10.1136\/bmjopen-2016-012567.","DOI":"10.1136\/bmjopen-2016-012567"},{"issue":"2","key":"10.1016\/j.jctube.2024.100425_b0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00002030-200401230-00015","article-title":"A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis","volume":"18","author":"Wallis","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.jctube.2024.100425_b0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1146\/annurev-pathol-011811-132458","article-title":"Tuberculosis pathogenesis and immunity","volume":"7","author":"Philips","year":"2012","journal-title":"Annu Rev Pathol"},{"issue":"3","key":"10.1016\/j.jctube.2024.100425_b0190","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/mi.2011.13","article-title":"Role of innate cytokines in mycobacterial infection","volume":"4","author":"Cooper","year":"2011","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.jctube.2024.100425_b0195","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","article-title":"The immune response in tuberculosis","volume":"31","author":"O'Garra","year":"2013","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.jctube.2024.100425_b0200","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.smim.2014.04.003","article-title":"Tumor necrosis factor alpha in mycobacterial infection","volume":"26","author":"Dorhoi","year":"2014","journal-title":"Semin Immunol"},{"issue":"2","key":"10.1016\/j.jctube.2024.100425_b0205","doi-asserted-by":"crossref","first-page":"e13901","DOI":"10.1111\/eci.13901","article-title":"Molecular mechanisms of glucocorticoid resistance","volume":"53","author":"Huang","year":"2023","journal-title":"Eur J Clin Invest"},{"issue":"9","key":"10.1016\/j.jctube.2024.100425_b0210","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V84.9.3063.3063","article-title":"Interleukin-6 prevents dexamethasone-induced myeloma cell death","volume":"84","author":"Hardin","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.jctube.2024.100425_b0215","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cyto.2016.08.003","article-title":"TNF activity and T cells","volume":"101","author":"Mehta","year":"2018","journal-title":"Cytokine"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579424000123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579424000123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T04:20:25Z","timestamp":1738729225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579424000123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":43,"alternative-id":["S2405579424000123"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2024.100425","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A teenage girl with altered mental status and paraparesis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2024.100425","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100425"}}